Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new opportunities for pharma growth. 15 November 2024
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
It is the third-most common disorder in the world. In the USA, close to 38 million people suffer from it. Globally, the number is a whopping 1 billion. We are talking about migraine, also often referred to as ‘super headaches’ — a condition more prevalent than diabetes, epilepsy, and asthma combined. 11 December 2017
Drug imports by Russia for the period of January-September of 2017 grew for the first time since 2014 and amounted to 108.700 tonnes, which is 6.5% more than in the same period a year ago. 11 December 2017
The occasion of World AIDS Day was as good as any for India to launch a National Strategic Plan 2017-24, aimed at eradicating HIV/ AIDS by 2030. The country has over 2.1 million people living with HIV, the third largest number of people with HIV in the world, reports The Pharma Letter’s India correspondent. 8 December 2017
Last week, the UK government published its latest annual update on its five year strategy to combat antimicrobial resistance (AMR). AMR, widely accepted as one of the major global challenges of the 21st century, is currently implicated in around 700,000 deaths worldwide, including 50,000 in the USA and Europe alone. 7 December 2017
French biotech company Cellectis has appointed Professor Stéphane Depil to the role of senior vice president R&D and chief medical officer. 5 December 2017
There are a few striking similarities between the world’s biggest biotech firm focused on rare diseases, and an emerging clinical stage pharma company that was set up just a couple of years ago. 5 December 2017
The global life sciences and pharmaceuticals sector is undergoing a wave of strategic M&A activity, as incumbents make acquisitions to enhance the technological capabilities they need to keep pace with the evolution of the industry. 4 December 2017
Alligator Bioscience today announced the expansion of its management team with the appointment of Charlotte Russell as chief medical officer and Peter Ellmark as vice president discovery. 4 December 2017
Following the formation of a dedicated strategic business unit oncology earlier this year within its pharmaceuticals division, Germany’s Bayer announced today it will further strengthen its strategic pharmaceutical research and development activities and bring them together under one leadership. 1 December 2017
The Supervisory Board of Selvita has appointed Edyta Jaworska to the position of a management board member, responsible for the development of its integrated drug discovery services. 30 November 2017
The Russian government has surprisingly decided to make concessions to domestic and global drugmakers operating in the country through the extension of the time, required for the mandatory labeling of drugs, reports The Pharma Letter’s local correspondent. 30 November 2017
Russian biotech and biosimilars company Biocad is launching production in North Africa. As part of these plans, the company will start manufacturing of anti-cancer drugs at the facilities of the Moroccan pharmaceutical company SothemaLabs, reports The Pharma Letter’s local correspondent. 29 November 2017
Denmark-based allergy specialist ALK-Abelló today announced that Helle Skov, executive vice president of product supply and a member of ALK's board of management, leaves the company by mutual agreement. 29 November 2017
Charlie Johnson, chief executive of antibody drug conjugate (ADC) specialist ADC Bio, considers some of the challenges and solutions involved with developing ADC therapeutics in an Expert View piece. 29 November 2017
Mads Krogsgaard Thomsen, Novo Nordisk employee for over a quarter of a century, says he has "been through all the miserable failures as well as the successes of the company, from products that are now off patent to those that don't yet have one." 28 November 2017
Following reports in Israeli press last week that struggling generics giant Teva Pharmaceutical Industries is gearing up to slash its global workforce, the company announced today a radical shakeup of its executive team which included, as expected, the ousting of R&D chief Michael Hayden. 27 November 2017
As the crackdown on Canadian drug company Concordia International continues for overcharging the UK’s National Health Service by more than £100 million over the past decade, India's drug price regulator the National Pharmaceutical Pricing Authority (NPPA) has identified over 601 suspected cases of overcharging where drug companies are not complying with the notified ceiling prices. 27 November 2017